News
Pharma/biotech organizations are implementing human-centric changes to address sources of volatility
The Crowe Executive Outlook Study finds 68% of pharmaceutical and biotech executives are actively increasing investments in change management.
.png?rev=9a1b39bb1ef2473a809a2eaf0bdbad28&w=468&hash=D27D96CA5AA8C004B64DC5D0B106B852)
Workforce, inflation, cybersecurity and business continuity cited among the highest risks.
Findings from the Crowe Executive Outlook Study, a joint research project from Crowe and Forbes, are featured in the debut report.
Findings from the Crowe Executive Outlook Study, a joint research project from Crowe and Forbes, are featured in the debut report.
Pharma/biotech organizations are implementing human-centric changes to address sources of volatility
The Crowe Executive Outlook Study finds 68% of pharmaceutical and biotech executives are actively increasing investments in change management.
Workforce, inflation, cybersecurity and business continuity cited among the highest risks.
Findings from the Crowe Executive Outlook Study, a joint research project from Crowe and Forbes, are featured in the debut report.
| News release | Date |
|---|---|
| 5/1/2023 | |
| 4/26/2023 | |
| 4/18/2023 | |
| 4/4/2023 | |
| 4/3/2023 | |
| 3/28/2023 | |
| 3/10/2023 | |
| 2/15/2023 | |
| 1/31/2023 | |
| 1/23/2023 | |
|
Crowe boosts its private equity group
1/19/2023
|
1/19/2023 |
| 1/5/2023 | |
| 12/2/2022 | |
| 11/9/2022 | |
| 9/14/2022 |
